1. 130P COM701 ± nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor. (December 2022) Authors: Sullivan, R.J.; Sharma, M.R.; Vaena, D.; Hamilton, E.; Izar, B.; Rasco, D.; Gainor, J.; D. Shepard, ; Papadopoulos, K.; Dumbrava, E.E.; Adewoye, H.H.; Ferre, P.J.; Ophir, E.; Patel, M.; Patnaik, A.; Chmielowski, B. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 159P COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant epithelial ovarian cancer. (December 2022) Authors: Yeku, O.; D. Shepard, ; Patel, M.; Fleming, G.; Vaena, D.; Rasco, D.; Chmielowski, B.; Sharma, M.R.; Hamilton, E.; Sullivan, R.J.; Papadopoulos, K.; Izar, B.; Cojocaru, G.; Ophir, E.; Ferre, P.J.; Dumbrava, E.E. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗